Silence Therapeutics PLC PDMR Shareholding (3659O)

TIDMSLN

RNS Number : 3659O

Silence Therapeutics PLC

29 May 2020

PDMR Shareholding

May 29, 2020

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on May 28th 15,800 Shares were purchased by Iain Ross, Executive Chairman of the Company, through his SIPP at GBP4.70 per share.

Following this purchase, Iain Ross is interested in 44,693 ordinary shares (0.05%) of the issued shared capital of the Company. The previously disclosed 25,000 shares held by Mr Ross did not include 3,893 shares that were already held in Mr Ross's SIPP and originate from his previous tenure with the Company that ended in 2010. The 44,693 ordinary shares now held by Mr Ross corrects for these previously undisclosed shares.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Iain Ross 
     ---------------------------  -------------------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------- 
 a)   Position / status            Executive Chairman 
     ---------------------------  -------------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  -------------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  -------------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  -------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------------- 
 a)   Description of               Ordinary Shares of 5 pence each in Silence 
       the financial instrument,    Therapeutics plc 
       type of instrument 
 
       Identification 
       code                         ISIN for Silence Therapeutics plc Ordinary 
                                    Shares: 
                                    GB00B9GTXM62 
     ---------------------------  -------------------------------------------- 
 b)   Nature of the transaction    Purchase of Ordinary Shares in Silence 
                                    Therapeutics plc 
     ---------------------------  -------------------------------------------- 
 c)   Prices(a) and volume(s)        Price      Volume 
                                      GBP4.70    15,800 
                                                ------- 
     ---------------------------  -------------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume           15,800 Ordinary Shares 
       - Price                       GBP74,260.00 
     ---------------------------  -------------------------------------------- 
 e)   Date of the transaction      28 May 2020 
     ---------------------------  -------------------------------------------- 
 f)   Place of the transaction     London Stock Exchange, AIM 
     ---------------------------  -------------------------------------------- 
 

Enquiries:

 
 Silence Therapeutics plc                     Tel: [phone] 
  Iain Ross, Executive Chairman                6900 
  Dr Rob Quinn, Chief Financial Officer 
  Investec Bank plc (Nominated Adviser and     Tel: +44 (0) 20 
   Broker)                                      7597 5970 
   Daniel Adams/Gary Clarence 
 European IR                                  Tel: +44 (0) 20 
  Consilium Strategic Communications           3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  [e-mail] 
 US IR                                         Tel: [phone] 
  Westwicke Partners 
  Peter Vozzo 
  [e-mail] 
 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHFZGZKRLKGGZG

(END) Dow Jones Newswires

May 29, 2020 04:37 ET (08:37 GMT)